Answers are grounded in this paper and cite their sources.
Toxic epidermal necrolysis (TEN) is a dermatological emergency with devastating morbidity and mortality rates. It is most often caused by medications. Management guidelines have focused on conservative measures, partly due to a previous lack of large randomized controlled trials evaluating systemic agents, and because experts have differing views on initiating active medical management. Tumour necrosis factor alpha (TNF-α) is a cytokine that is involved in immune defence against various infectious agents by exerting a powerful anti-inflammatory effect. Inhibition of TNF-α is well established in the management of noninfectious inflammatory (including dermatological) conditions. Patients with TEN have prominent expression of TNF-α in keratinocytes and macrophages in affected skin as well as in blister fluid. This review article aims to summarize the recent and emerging evidence for using anti-TNF-α treatment, particularly etanercept, in the management of TEN.
No takes yet. Share an insight, caveat, or question.
Uppal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: